利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.019 秒)

    Anti-ischemic pharmaceutic compositions
    1.
    发明授权
    Anti-ischemic pharmaceutic compositions 失效
    抗缺血药物组合物

    公开(公告)号：US4407801A

    公开(公告)日：1983-10-04

    申请号：US306224

    申请日：1981-09-28

    申请人： Jean-Claude Arnaud ,  Michelle Devissaguet

    发明人： Jean-Claude Arnaud ,  Michelle Devissaguet

    IPC分类号： A61K9/20 ,  A61K31/495 ,  A61K31/70

    CPC分类号： A61K9/2018 ,  A61K31/495 ,  A61K9/2059

    摘要： The subject of the invention is a novel pharmaceutical composition, especially having an anti-ischaemic action, containing, in combination, a high dosage (within the range of from 20 to 80 mg) of the dihydrochloride (or another mineral or organic salt) of 1-(2,3,4-trimethoxybenzyl)piperazine and a disintegrating agent, such as mannitol or sodium carboxymethyl starch, that has the effect of liberating the salt of 1-(2,3,4-trimethoxybenzyl)piperazine virtually instantaneously in the organism, this composition being, furthermore, advantageously enclosed in a thin coating film or held together by a binder that is itself readily disintegrated in situ in the organism in such a manner that it makes possible a "flash" action, that is to say a virtually instantaneous action, of the above-mentioned salt in situ. This composition is administered to the patient at a dosage of from 20 to 80 mg/day.

    摘要翻译： 本发明的主题是特别是具有抗缺血作用的新型药物组合物，其组合含有二盐酸盐（或另一种矿物或有机盐）的高剂量（在20至80mg范围内） 1-（2,3,4-三甲氧基苄基）哌嗪和崩解剂，如甘露糖醇或羧甲基淀粉钠，其实际上可以瞬间释放1-（2,3,4-三甲氧基苄基）哌嗪的盐 此外，该组合物还有利地封闭在薄的涂膜中或通过粘合剂保持在一起，所述粘合剂本身容易在生物体中原位分解，使得可能发生“闪光”作用，也就是说 几乎瞬间作用，上述盐原位。 将该组合物以20至80mg /天的剂量施用于患者。

    Pyrrolo [1,2-a] thieno [3,2-f] (1,4) diazepines
    3.
    发明授权
    Pyrrolo [1,2-a] thieno [3,2-f] (1,4) diazepines 失效
    吡咯（1,2-A）噻吩（3,2-F）（1,4）二氮杂

    公开(公告)号：US5190939A

    公开(公告)日：1993-03-02

    申请号：US665812

    申请日：1991-03-07

    申请人： Sylvain Rault ,  Michel Boulouard ,  Patrick Dallemagne ,  Max Robba ,  Beatrice Guardiola ,  Michelle Devissaguet

    发明人： Sylvain Rault ,  Michel Boulouard ,  Patrick Dallemagne ,  Max Robba ,  Beatrice Guardiola ,  Michelle Devissaguet

    IPC分类号： A61K31/55 ,  A61P1/00 ,  A61P1/04 ,  A61P3/06 ,  A61P9/10 ,  A61P25/00 ,  A61P25/18 ,  A61P25/28 ,  C07D495/14 ,  C07D498/22

    CPC分类号： C07D495/14

    摘要： The invention relates to compounds of general formula I: ##STR1## in which: R.sub.1 represents a radical of general formula (Z.sub.0), (Z.sub.1), (Z.sub.2), (Z.sub.3) or (Z.sub.4) ##STR2## R.sub.2 represents a methylene radical, a hydroxymethylene radical, a carbonyl radical or a radical of general formula (Y.sub.1), (Y.sub.2), (Y.sub.3) or (Y.sub.4): ##STR3## or, with R.sub.12 and the nitrogen atom to which they are attached, forms a radical of general formula (W): ##STR4## R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12 and n being as defined in the description, medicinal products containing the same and a method-of-treating metabolic ailments therewith.

    摘要翻译： 本发明涉及通式I的化合物：其中：R1表示通式（ZO），（Z1），（Z2），（Z3）或（Z4）的基团（Z0） （Z 1）（Z 3）（Z 3）（Z 3）（Z 3）（Z 4）R 2表示亚甲基，羟基亚甲基，羰基或通式（Y1） （Y3）或（Y4）：（Y1）（Y1）（Y2）（Y3）（Y4）或与R12及其相连的氮原子形成 通式（W）的基团：其中R 3，R 4，R 5，R 6，R 7，R 8，R 9，R 10，R 11，R 12和n如说明书中所定义， 治疗代谢疾病。

    Acylbenzoxazolinones compounds
    5.
    发明授权
    Acylbenzoxazolinones compounds 失效
    氨基苯甲酸酯化合物

    公开(公告)号：US5147883A

    公开(公告)日：1992-09-15

    申请号：US708515

    申请日：1991-05-31

    申请人： Hocine Aichaioui ,  Daniel Lesieur ,  Charles Lespagnol ,  Michelle Devissaguet ,  Beatrice Guardiola

    发明人： Hocine Aichaioui ,  Daniel Lesieur ,  Charles Lespagnol ,  Michelle Devissaguet ,  Beatrice Guardiola

    IPC分类号： A61K31/42 ,  A61K31/423 ,  A61K31/44 ,  A61K31/455 ,  A61K31/47 ,  A61P7/02 ,  A61P9/08 ,  A61P9/10 ,  C07D263/52 ,  C07D263/58 ,  C07D263/60 ,  C07D263/62 ,  C07D413/06

    CPC分类号： C07D263/52 ,  C07D263/58 ,  C07D263/60 ,  C07D413/06

    摘要： Compounds of general formula (I): ##STR1## in which: R.sub.1 represents a hydrogen atom or a lower alkyl group,A represents a hydrogen atom, and in this case B represents a group CO-G, G being:either a heteroaryl group selected from furan, indole, pyrrole, pyridine, quinoline, isoquinoline and benzofuran, optionally substituted with one or more lower alkyl or lower alkoxy groups or a halogen atoms,or a linear or branched lower alkyl group substituted with a carboxyl group,or a linear or branched lower alkenyl group substituted with a carboxyl group,or a phenyl or naphthyl group substituted with a carboxyl group,or alternatively A forms with B a group CO(CH.sub.2).sub.n CH(CH.sub.3) with n being a integer equal to 1, 2, 3 or 4, the CO group being attached to the aromatic ring of the benzoxazolinone at the 5- or 6-position,as well as, where appropriate, their isomers and, when the compound of formula (I) possesses a carboxylic acid group, their addition salts with a pharmaceutically acceptable base, and, when the compound of formula (I) contains a basic group, their addition salts with a pharmaceutically acceptable acid, it being understood that lower alkyl and lower alkenyl mean linear or branched groups comprising from 1 to 6 carbon atoms.Medicinal products.

    摘要翻译： 通式（I）的化合物：其中：R1表示氢原子或低级烷基，A表示氢原子，在这种情况下，B表示CO-G基团，G表示： 选自呋喃，吲哚，吡咯，吡啶，喹啉，异喹啉和苯并呋喃的杂芳基，任选被一个或多个低级烷基或低级烷氧基或卤素原子取代，或被羧基取代的直链或支链低级烷基， 或被羧基取代的直链或支链的低级链烯基或被羧基取代的苯基或萘基，或者与B a基团CO（CH 2）n CH（CH 3）形成A，其中n为等于1的整数 ，2,3或4，所述CO基团在5-或6-位连接于苯并恶唑啉酮的芳环，并且在适当的情况下连接其异构体，并且当式（I）化合物具有羧酸 酸基，它们与药学上可接受的碱的加成盐 并且当式（I）化合物含有碱性基团时，其与药学上可接受的酸的加成盐，应理解为低级烷基和低级烯基表示包含1至6个碳原子的直链或支链基团。 药用产品。